secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2025-02-12T23:59:59+00:00
Accession:  0001193125-25-025099
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Dr. Jerry Wang exits AnHeart Therapeutics CEO role after taletrectinib milestones achieved
--------------------------------------------------------------------------------

- Dr. Wang departed as CEO of AnHeart Therapeutics, a Nuvation Bio subsidiary, on Feb. 12, 2025.
- Departure follows China NMPA approval of taletrectinib for advanced ROS1-positive NSCLC.
- Also follows FDA acceptance and priority review of NDA for taletrectinib in advanced ROS1-positive NSCLC.
- Dr. Wang resigned from Nuvation Bio board effective Feb. 11, 2025; no disagreement with company.
- Role eliminated as redundant after successful integration of AnHeart Therapeutics post-merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312525025099/0001193125-25-025099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312525025099/d839065d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-025099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer